Gina Mauro

Vice President of Content, OncLive and Cancer Network
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

Articles

Blinatumomab Plus Ponatinib Shows Survival Advantage Over Chemo/TKI Regimen in Ph+ ALL

December 7th 2025

Initial results from the phase 3 GIMEMA ALL2830 trial support the use of this chemotherapy-free approach as a new SOC for adult Ph-positive ALL.

Epcoritamab Plus Rituximab and Lenalidomide Improves PFS in Pretreated Follicular Lymphoma

December 7th 2025

The addition of epcoritamab to lenalidomide and rituximab improved PFS and ORR vs the combination alone in relapsed/refractory follicular lymphoma.

Survival in Induction Chemotherapy AML Studies May be Predictable by MRD

December 6th 2025

Future AML study analyses may focus on measurable residual disease to predict OS through non-intensive modern treatment backbones.

Venetoclax-Based, Fixed-Duration Regimens Match Continuous Ibrutinib in Frontline CLL

December 6th 2025

Fixed-duration venetoclax combinations delivered PFS comparable with continuous ibrutinib in the phase 3 CLL17 trial.

Buparlisib Plus Paclitaxel Fails to Yield OS Benefit in PD-1/PD-L1–Pretreated HNSCC

October 21st 2025

Buparlisib plus paclitaxel did not show an improvement in OS vs paclitaxel alone in PD-1/PD-L1–pretreated recurrent/metastatic HNSCC.

Zabilugene Almadenorepvec Plus SOC Therapy Yields OS Benefit in Untreated Metastatic PDAC

October 20th 2025

Zabilugene almadenorepvec plus SOC therapy was active in patients with treatment-naive metasatic PDAC.

DESTINY-Breast09 Subgroup Data Show Clinically Meaningful PFS Benefit T-DXd/Pertuzumab in HER2+ Breast Cancer

October 20th 2025

T-DXd plus pertuzumab generated consistent PFS benefits among HER2+ breast cancer subgroups.

First-Line Disitamab Vedotin Plus Toripalimab Yields Survival Advantage in HER2+ Advanced Urothelial Cancer

October 19th 2025

Frontline disitamab vedotin plus toripalimab significantly improved PFS and OS in HER2-expressing locally advanced or metastatic urothelial carcinoma.

Second-Line Sacituzumab Tirumotecan Displays PFS Benefit in EGFR+ NSCLC

October 19th 2025

Sacituzumab tirumotecan reduced the risk of progression or death by 51% in nonsquamous EGFR-mutated NSCLC resistant to EGFR TKIs.

First-Line Tarlatamab/Chemoimmunotherapy Yields Early Efficacy Signals in ES-SCLC

October 18th 2025

First-line treatment with tarlatamab plus chemoimmunotherapy and anti–PD-L1 maintenance therapy generated durable responses in patients with ES-SCLC.

First-Line Alectinib Yields Clinically Meaningful OS Benefit in Advanced ALK+ NSCLC

October 17th 2025

First-line alectinib produced a clinically meaningful overall survival benefit in advanced ALK-positive non–small cell lung cancer.

AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights

September 22nd 2025

Oncology experts discuss the role of the Scout AI platform in aiding trial matching and treatment selection in oncology.

Perioperative Pembrolizumab Plus Chemo Yields Improved Survival, Responses in Early-Stage Resectable NSCLC

September 8th 2025

Perioperative pembrolizumab demonstrated improved mPR, pCR, EFS, and OS in patients with early-stage resectable NSCLC and any nodal status.

Mosunetuzumab Demonstrates High Response Rates in Treatment-Naive MZL

September 5th 2025

Frontline treatment with mosunetuzumab showed high antitumor activity in patients with marginal zone lymphoma regardless of risk status.

Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer

June 21st 2025

Raludotatug deruxtecan showed promising clinical activity in patients with heavily pretreated, platinum-sensitive ovarian cancer.

Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma

June 16th 2025

Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma.

Consolidation Blinatumomab Improves Efficacy Vs Chemo in Newly Diagnosed BCR::ABL1– B ALL

June 15th 2025

The E1910 trial results showed improved OS and RFS with blinatumomab vs chemotherapy in patients with newly diagnosed BCR::ABL1-negative B ALL.

BGB-16673 Is Safe, Elicits Nearly 85% ORR in Relapsed/Refractory CLL/SLL

June 15th 2025

BGB-16673 showed a favorable safety profile and promising antitumor activity in relapsed/refractory CLL/SLL, with responses seen across baseline mutations.

Early Daratumumab in Patients With Myeloma Experiencing MRD Relapse Delays Clinical Progression

June 15th 2025

PREDATOR-MRD data can serve as proof of concept for larger trials with novel MRD assessment techniques.

Addition of Dasatinib to Induction/Consolidation Fails to Boost Survival in Core-Binding Factor AML

June 14th 2025

Dasatinib added to induction and consolidation, then continued as maintenance, did not improve survival in core-binding factor AML.